P. Rendo

发表

Plasma erythropoietin levels in the oldest old

C. Musso, C. Musso, H. Joseph, 2004, International Urology and Nephrology.

Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa

J. Korth-Bradley, J. Fuiman, Lynne Smith, 2017, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection.

P. Rendo, N. del Pino, J. Fernández, 1997, Journal of viral hepatitis.

A double‐blind controlled trial of recombinant interferon‐α2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels

P. Rendo, J. Fernández, L. Viola, 1997 .

Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial.

N. Vain, L. Prudent, H. Donato, 2000, Pediatrics.

α-Interferon therapy induces improvement of platelet counts in children with chronic idiopathic thrombocytopenic purpura

G. Schvartzman, M. Rapetti, H. Donato, 2001 .

Factors that influence the bleeding phenotype in severe hemophilic patients

J. Korth-Bradley, P. Rendo, F. Shafer, 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Low levels of serum erythropoietin in children with endemic hemolytic uremic syndrome

M. Rapetti, H. Donato, R. Exeni, 1998, Pediatric Nephrology.

Serum hepatitis C virus RNA in anti-HCV negative hemodialysis patients

R. Valtuille, P. Rendo, J. Fernández, 1996 .

The Role of Transfusion-Transmitted Virus in Patients Undergoing Hemodialysis

R. Valtuille, F. Fay, P. Rendo, 2002, Journal of clinical gastroenterology.

Evidence of Hepatitis C Virus Passage Across Dialysis Membrane

R. Valtuille, P. Rendo, N. del Pino, 1998, Nephron.

Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects

L. Valentino, J. Korth-Bradley, I. Elezović, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.

J. Korth-Bradley, C. Altisent, Lynne Smith, 2016, Clinical therapeutics.

Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities

Lynne Smith, P. Rendo, F. Shafer, 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B

Y. Zhao, J. Sun, X. Wang, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use

M. Makris, A. Hassoun, A. Tagliaferri, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B

K. Kuliczkowski, J. Korth-Bradley, K. Kavaklı, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy

M. Carr, N. Vendetti, P. Rendo, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A

J. Korth-Bradley, A. Płotka, P. Rendo, 2018, Clinical and translational science.

Clinical experience with moroctocog alfa (AF‐CC) in younger paediatric patients with severe haemophilia A: Two open‐label studies

J. Korth-Bradley, K. Kavaklı, J. Fuiman, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A

Mark P Smith, J. Korth-Bradley, Y. Wali, 2018, Blood.

Evaluation of Two Secondary Prophylaxis Regimens of Recombinant Factor IX(r-IX) in Moderately Severe to Severe( FIX ≤2%) Hemophilia B Patients

J. Korth-Bradley, Lynne Smith, P. Rendo, 2012 .

Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset

M. Carr, B. Tortella, J. Korth-Bradley, 2021, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B

R. Labadie, J. Korth-Bradley, R. Wu, 2017, Thrombosis and Haemostasis.

Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings

V. Jiménez‐Yuste, J. Korth-Bradley, A. Cid, 2015, Thrombosis and Haemostasis.

Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B

K. Kuliczkowski, J. Korth-Bradley, K. Kavaklı, 2014 .

First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China

J. Korth-Bradley, R. Wu, Lihong Xu, 2021, Medicine.

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies

Jie Jin, Depei Wu, J. Korth-Bradley, 2020, Journal of blood medicine.

Hepatitis C virus RNA and long‐term response to recombinant interferon‐α2b in patients with chronic hepatitis C

R. Terg, P. Rendo, H. Tanno, 1995 .

Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up.

R. Valtuille, P. Rendo, L. Lef, 2002, Clinical nephrology.

Interferon DNA polymorphism in chronic leukemia.

E. Rozenblum, J. S. Avalos, P. Rendo, 1994, Leukemia & lymphoma.

Influence of Hemodialysis Procedure on HCV RNA Detection in Serum and Peripheral Blood Mononuclear Cells

R. Valtuille, F. Fay, P. Rendo, 2004, Renal failure.

Hepatitis G Virus Infection in Hemodialysis Patients and Its Relationship with Hepatitis C Virus Infection

R. Valtuille, P. Rendo, J. Fernández, 2000, American Journal of Nephrology.

Massive plasmocytosis due to methimazole‐induced bone marrow toxicity

P. Rendo, J. González, D. Breier, 2001, American journal of hematology.

PHASE II TRIAL OF RECOMBINANT INTERFERON-ALPHA 2B IN PATIENTS WITH ADVANCED INTRACTABLE MULTIDRUG-RESISTANT PULMONARY TUBERCULOSIS: LONG TERM FOLLOW-UP

L. Montaner, D. Palmero, P. Rendo, 1999 .

Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up.

D. Palmero, P. Rendo, E. Abbate, 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects

L. Valentino, J. Korth-Bradley, I. Elezović, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.